News | Pulmonary Embolism | November 03, 2015

Study Examines Anticoagulants as Outpatient Treatment for Stable Pulmonary Embolism

Trial will monitor low-risk PE patients to see if rivaroxaban reduces time in the hospital, recurrent events and healthcare costs

pulmonary embolism, low-risk PE, rivaroxaban, Xarelto, MERCURY PE trial

Image courtesy of Philips Healthcare

November 3, 2015 — Pulmonary embolism (PE) is a potentially life-threatening condition that occurs, for example, when a blood clot travels to the lungs. It requires immediate medical attention and often hospitalization, which in turn leads to higher costs for both patients and healthcare providers. Now, a new trial based on recent research is examining the benefits of treating low-risk pulmonary embolism (PE) patients with rivaroxaban (Xarelto) and discharging them early from the hospital to complete treatment at home.

The trial, called MERCURY PE (MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department), is a randomized, open-label, parallel-group study of 300 PE patients that is being conducted in 45 centers in the United States.

The primary endpoint is the total number of days in the hospital in the first 30 days for the treatment of PE or deep vein thrombosis (DVT), whether for a primary event or a recurrence. Secondary endpoints include: recurrence of non-fatal and fatal blood clots (PE or DVT); number of unplanned hospital visits for PE/DVT symptoms and/or bleeding; any other hospitalization; and patient-reported outcomes. Associated costs also will be evaluated.

"Hospitals across the U.S. have varying protocols in place for managing patients with pulmonary embolism, but the typical standard of care requires the patient to be admitted to the hospital for treatment, which drives up costs," said Paul Burton, M.D., Ph.D., vice president, medical affairs, Janssen Pharmaceuticals. “The MERCURY PE trial will specifically look at how PE patients identified as low-risk are managed, and if these patients have fewer overall hospital days, less events and lower costs when treated with rivaroxaban and immediately discharged compared to patients admitted and given standard treatment."

MERCURY PE builds on prior research, including a recently published study conducted by Jeffery Kline, M.D., of Indiana Health University that found that low-risk PE or DVT patients, when prescribed Xarelto and immediately discharged, had no recurrent events while on therapy. Additionally, no major or clinically relevant bleeding events were observed. A companion study found that low-risk PE/DVT patients who were prescribed Xarelto had significantly lower medical costs than those admitted and given standard treatment.

MERCURY PE is part of the EXPLORER global cardiovascular research program for Xarelto.

For more information:

Related Content

Smokers Have More Pulmonary Emboli, Leading to Higher Hospital Readmission Rates

Image courtesy of the American Heart Association

News | Pulmonary Embolism | October 18, 2019
Patients with lung blood clots who smoke are more likely to be readmitted for lung blood clots than nonsmokers,...
Aidoc Announces CE Mark for AI-based Pulmonary Embolism Workflow Tool
News | Pulmonary Embolism | March 04, 2019
Artificial intelligence (AI) radiology solution provider Aidoc announced the commercial release of its CE-marked...
First Balloon Pulmonary Angioplasty for Chronic Pulmonary Embolism Performed in Illinois
News | Pulmonary Embolism | October 23, 2018
Daniel J. Schimmel, Jr., M.D., MS, a cardiologist at Northwestern Memorial Hospital, recently performed the first...
Xarelto Associated With Reduced Hospital Time and Costs for Low-risk PE Patients
News | Pulmonary Embolism | June 29, 2018
Results from the MERCURY PE study showed that low-risk pulmonary embolism (PE) patients treated with Xarelto (...
Novel Way to Treat Blood Clots in Lungs, pulmonary embolism, Found Safe and Effective. #SCAI, #SCAI2018
News | Pulmonary Embolism | May 11, 2018
Results of the FlowTriever Pulmonary Embolectomy (FLARE) study were presented as late-breaking clinical science at the...
Technology | Pulmonary Embolism | March 01, 2017
March 1, 2017 — BTG plc announced U.S.
Pulmonary embolism, toshiba

A pulmonary embolism visualized on a CTA scan using SureSubtraction software on a Toshiba Aquilion One Vision CT scanner. 

Feature | Pulmonary Embolism | March 28, 2016 | Alain T. Drooz, M.D., FSVM, and David J. Spinosa, M.D.
Acute pulmonary embolism (PE) can pose a major treatment quandary for clinicians.
Ekos for PE

The Ekos catheter was recently cleared by the FDA to aid in infusion and in breaking down pulmonary emboli faster than traditional lytic treatment alone.

Feature | Pulmonary Embolism | October 03, 2014 | James M. McCabe, M.D., FACC, University of Washington, Seattle
Acute intermediate-risk pulmonary emboli (PE) in normotensive patients with right ventricle dysfunction present the...